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The review is dedicated to relationships between the blood pressure and body mass. Endothelial 
dysfunction and imbalance of neurohumoral systems, namely, the pathological increase in the 
activity of the renin-angiotensin system, in combination with obesity are the main mechanisms 
of the of the hypertonic disease pathogenesis. Here we discuss the research on polymorphism 
of the renin angiotensinic system genes and the endothelial synthase nitric oxide gene. The 
difficulty lies in the correct assessment of associations of alleles which have clinical signifi-
cance. It is essential to determine precisely the associations of gene polymorphisms in the 
hypertonic disease with obesity. This provides an opportunity to identify new personified 
approaches to the treatment of patients with this complex pathology.
K e y w o r d s: endothelial nitric oxide synthase, renin-angiotensin system, gene polymorphism, 
hypertonic disease, obesity.
Introduction
Genetic polymorphism is the presence of al-
leles, different variants of one gene, in a pop-
ulation. Herewith the allele can be considered 
as polymorphism, if the frequency of its oc-
currence in the population is not less than 1 %. 
Human genome polymorphisms are decisive 
for the development, progression and thera-
peutic intervention for various pathological 
conditions. Polymorphisms in different genes 
contribute to functional changes in the protein 
activity or expression. Therefore, it is impor-
tant to clarify not only the effect of individual 
polymorphisms on the function of genes, but 
also the relationship between polymorphisms 
in different genes, especially those that are 
functionally related [1]. The structure and ac-
tivity of the protein products of the gene may 
depend on the variant of the allele. 
It is generally believed that the environmen-
tal and genetic factors influence the formation 
of arterial hypertension (AH) phenotype and 
determine its progression. At present, a sig-
nificant role in the pathogenesis of polygenic 
diseases, in particular, arterial hypertension 
(AH), is given to genetic polymorphisms. 
A number of studies have revealed the connec-
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tion between numerous polymorphic markers 
of genes, coding the components of the renin-
angiotensin-aldosterone system (RAAS), the 
sympathoadrenal system (SAS), endothelial 
and other factors with the AH development.
All over the world, hypertension (HD) oc-
cupies a leading place in the structure of car-
diac pathology and, due to its spreading among 
people of working age and early development 
of complications that lead to prolonged dis-
ability and invalidization is an urgent medical 
and social problem. Arterial hypertension (AH) 
as a starting and modelling mechanism in-
duces the development of pathological chang-
es in the cardiovascular system and internal 
organs [1]. At present, AH goes beyond med-
ical problems taking a multidisciplinary and 
socially significant character.
The risk of complications and death in the 
AH patients increases according to numerous 
concomitant risk factors. AH in isolated form 
occurs only in 8 % of cases, whereas in others 
it is combined with one or more factors of 
cardiovascular risk. In 20–22 % of cases AH 
is combined with hyperlipidemia, in 30 % with 
hyperlipidemia and obesity, whereas 32 % of 
patients suffered from dyslipidemia, obesity 
and various disorders of carbohydrate me-
tabolism — glucose intolerance, insulin resis-
tance, 2nd type diabetes mellitus (DM 
type 2) [2].
There are many researches on the genetic 
mechanisms of susceptibility to cardiovascular 
disease (CVD). Recently, it has been proved 
that genetic predisposition contributes to the 
inheritance of AH. The genetic factors can play 
a significant role in the development of AH 
confirming its polygenic nature. Therefore, the 
search for the genetic markers of the renin-
angiotensin system ( RAS) responsible for the 
development of AH and related disorders, 
namely obesity, and  carbohydrate metabolism 
is an urgent problem of great interest to many 
scientists. The genetic polymorphism [3] is 
proved to be a significant factor affecting a 
level of expression of endothelial nitric oxide 
synthase (eNOS). The level and activity of NO 
depend on the allelic variant of the NO syn-
thesis genes. In this regard, the study on the 
genes involved in the synthesis of NO (primar-
ily eNOS) has become an important step in 
identifying the genetic risk factors for CVD. 
Their study is complex because of the large 
number of genes that can participate in the 
formation of hereditary predisposition either 
independently or through interaction with each 
other. Recently, a huge amount of information 
has been accumulated regarding polymorphic 
regions of the human genome as a whole, as 
well as their correlation with various diseases.
Modern strategy for researching a genetic 
predisposition is based on the study of the 
polymorphic markers of candidate genes. 
These are genes, the expression products of 
which are involved in the pathogenesis of this 
disease. Importantly, the genetic predisposition 
to such multifactorial pathologies, as АН and 
obesity is also polygenic, which requires an 
assessment of the integrated genetic panel. To 
clarify the nature of the link between the gene 
and metabolic state of the organism, single 
nucleotide polymorphisms (SNPs) are inves-
tigated. SNPs are defined as loci with alleles 
that differ at a single base, with a frequency 
of at least 1 % in a random set of individuals 
in the population [4].
Nowadays, the polymorphism of dozens of 
genes has been found that claims the role of 
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hereditary markers of atherosclerosis, AH, 
coronary heart disease (CHD), myocardial 
infarction, chronic heart failure (CHF), and 
microvascular complications in type 2 diabe-
tes, namely, diabetic retinopathy and nephrop-
athy [5,6]. However, their clinical and prog-
nostic values are not completely comprehen-
sible; besides, the literature data are obviously 
contradictory.
The pathogenesis of hypertensive disease 
(HD) in obese persons is a multicomponent 
process, including an increase of circulating 
blood volume, vasoconstriction, and hyperac-
tivity of sympathoadrenal, renin angiotensin 
systems, and metabolic disorders. One of the 
early phases of the pathogenesis of this com-
plex pathology is the development of endothe-
lial dysfunction (ED).
Due to the fact that the leading mechanisms 
for the development of cardiovascular disease 
are ED and the imbalance of the neurohu-
moral systems of the body, in particular the 
pathological increase in the activity of the 
renin-angiotensin system (RAS), it is the 
search and study of the polymorphisms of the 
genes of these systems is the most relevant 
today.
The genome-wide association studies 
(GWASs) have identified thousands of genes 
and genetic variants (mainly SNPs) that con-
tribute to the complex diseases in humans. At 
the heart of the GWAS-based approaches lies 
the “common variant–common disease” hy-
pothesis. The arrival of Next-Generation 
Sequencing (NGS) technologies facilitated a 
shift in focus from common to rare variants 
and provided the opportunity to unravel the 
genomic architecture underlying a hyperten-
sion risk.
Neurohumoral system in regulation 
of vascular tone and endothelial-de-
pendent vasodilation in patients with 
hypertonic disease with obesity
The main components of the renin-angiotensin 
system (RAS) are angiotensinogen (AGT), 
angiotensin converting enzyme (ACE) and 
angiotensin II (AT II) in patients with AH.
For many decades considerable attention 
has been paid to determining the role of RAS 
in the development of cardiovascular disor-
ders, namely in the pathogenesis of AH. RAS 
plays a special role in vasoconstriction and 
vasodilation, regulating long-term blood pres-
sure. Juxtaglomerular kidney cells secrete the 
enzyme renin. Renin proteolizes the inactive 
peptide of angiotensinogen, converting it into 
angiotensin I (AT I). AT I is then transformed 
into AT II using ACE.
AT II is one of the strongest vasoconstric-
tors. In kidneys, AT II leads to the contraction 
of glomerular arterioles, thus changing the 
glomerular filtration rate. In the adrenal cortex, 
AT II causes the release of aldosterone, which 
in turn affects the renal tubules, which leads 
to reabsorption of the majority of sodium and 
water ions from the urine due to displacement 
of potassium ions in the renal tubules. 
Aldosterone also affects the central nervous 
system, increasing the appetite of humans to 
salt and causing a feeling of thirst. Besides, 
AT II is able to increase the inflammatory 
potential, to provoke oxidative stress and en-
dothelium dysfunction, to activate atheroge-
nesis [7].
Two types of receptors are involved in the 
implementation of AT II influence on the heart 
and blood vessels. The receptors of AT II type 
1 (AT1 receptors) mediated  the main physi-
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ological and pathophysiological effects of AT 
II whereas the role of type 2 receptors (AT2 
receptors) remains controversial. Under normal 
conditions, they are present in a small amount 
in the vascular endothelium, but their expres-
sion significantly increases in various patho-
logical conditions associated with inflamma-
tion and remodelling of the heart and vessels: 
AH, atherosclerosis, DM type 2, myocardial 
infarction [8].
It was determined that AT II participates in 
the regulation of growth and development of 
adipose tissue [9]. Today it is known that the 
formation of AT II is not limited to the system 
circulation, it can be synthesized in a variety 
of tissues. In recent years much attention has 
been paid to adipose tissue, which is no longer 
considered only as an energy depot. 
The increased levels of adipocyte-secreted 
angiotensin are an important link between 
visceral obesity and ED, as evidenced by the 
correlation between the “waist circumference 
/ hip circumference” and the level of RNA 
angiotensinogen (AGT) of visceral and subcu-
taneous adipose tissue. Further enhancement 
of the AT II production at the tissue level stim-
ulates the secretion of superoxide — a leading 
factor in the etiology of ED. Thus, the activa-
tion of vascular RAS in subjects with abdom-
inal obesity should be considered as a leading 
mechanism of ED [10].
At present, the leading role of endothelium 
and nitric oxide (NO) in the genesis of cardio-
vascular complications of HD has been prov-
en. Endothelium is rightly called the largest 
endocrine gland of the body.
In physiological conditions, there is pre-
dominance of secretion of substances that 
cause relaxation, one of which, nitric oxide 
(NO) controls the basal tone of arterial vessels 
and, as a consequence, the blood pressure 
level. NO is a universal regulator of physio-
logical functions, in particular a powerful 
vasodilator. For HD, the main factor in the 
development of ED is the reduction of NO 
synthesis with preserved or increased secre-
tion of vasoconstrictors (endothelin-1, angio-
tensin II), which aggravate endothelium-de-
pendent relaxation, lead to the degradation 
and changes in the cytoarchitectonics of blood 
vessels. The main target of NO is soluble 
guanylate cyclase, the heme of which is a 
receptor for NO. The heme-linked NO in-
duces soluble guanylate cyclase, which leads 
to the enhanced synthesis of cyclic guanosine 
monophosphate (cGMP). Nitric oxide is 
formed in endothelial cells from L-arginine 
under the action of enzymes of the NO-
synthase system — constitutional neuronal 
(NO-synthase type 1, NOS 1 or nNOS), “in-
ducible” (NO-synthase type 2, NOS 2 or 
iNOS) and constitutional endothelial (NO-
synthase type 3, NOS 3 or eNOS). In the ac-
tive form all three isoforms are homodimers 
having a molecular weight of 130 (iNOS), 
135 (eNOS) and 160 (nNOS) kDa [11]. The 
formation of NO is regulated by altering the 
expression or activity of the еNOS enzyme 
itself, as a result, of changes in the activity of 
either cofactors, or endogenous inhibitors.
A number of studies have shown that a 
deficiency of NO in the blood leads to a num-
ber of CVDs. The risk of AH significantly 
increases with the excess body weight and 
obesity. Body mass closely correlated with BP. 
In some studies at the population level, it has 
been shown that overweight is an independent 
risk factor for hypertension. In recent years, 
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the term “obesity-induced hypertension” has 
appeared [12].
In connection with the study of mechanisms 
that regulate energy metabolism and provide 
neurohumoral homeostasis, new concepts have 
been rebuilt for the presence of pathogenetic 
links between excess body weight and in-
creased levels of blood pressure (BP). The 
effect of excess body weight on the level of 
BP depends on the genetic and neurobiological 
mechanisms that underlie the development of 
obesity.
Obesity contributes to the development of 
AH, and AH can cause a decrease in the sen-
sitivity of peripheral tissues to insulin and 
further obesity [13]. The probability of devel-
opment of AH in persons with excess body 
weight is 50 % higher than in those with nor-
mal body mass (Framingham Study) [14]. 
About 75 % of cases of AH are associated with 
obesity, but the mechanism by which it pro-
motes the development of AH is not yet fully 
studied. A rise in body weight by 5 % in-
creases the risk of AH by 30 % over four years. 
The frequency of AH increases to 55 % in 
those who had BMI greater than 30 kg/m2 
regardless of gender and age [15]. In a number 
of observations, attention was drawn to the fact 
that along with the degree of obesity a sig-
nificant factor in the cardiovascular disease is 
a mode of the distribution of adipose tissue. It 
is abdominal obesity [16], which is mainly 
located in the upper half of the body more 
often than the accumulation of fat in the lo wer 
half of the body (hyoid or peripheral), is com-
bined with cardiovascular disease and morta-
lity, accompanied more often by a violation of 
glucose tole rance, diabetes mellitus and dys-
lipidemia. 
Polymorphism of the renin-
angiotensin system genes and 
cardiometabolic risk
One of the key components of RAS is angio-
tensin converting enzyme (ACE). Normally, 
in different people, the ACE levels in blood 
plasma can vary up to 5 times. In a particular 
person, the ACE level is fairly stable. Such 
fluctuations in the level of ACE among people 
are caused by the polymorphism of the ACE 
gene. The ACE gene is charted in chromosome 
17q23. In the 16th intron of the ACE gene, an 
insertion-deletion (I/D) polymorphism 
(rs1799752) was found, which is one of four 
SNPs representing perhaps the best studied 
ACE SNP. It is actually not a single nucleotide 
polymorphism at all; instead, it is an insertion/
deletion of an Alu repetitive element of 287 
pairs of nucleotides in intron of the ACE gene. 
Alleles containing the insertion are called “I” 
alleles, and “D” alleles lack the repetitive ele-
ment. The Alu-repeat deletion results in an 
increase in the expression of the ACE gene. In 
this case, there was a correlation between D 
alleles and the level of ACE in blood, lymph 
and tissues. The level of ACE in serum in 
healthy people who are homozygous for D 
allele (DD genotype was observed in approx-
imately 36 % of people) was almost twice as 
high as in homozygous for I allele (II - geno-
type, about 17 % of people) and had an aver-
age value in heterozygous — ID genotype 
(47 %). The gene polymorphism is also as-
sociated with ACE level in the human heart. 
Thus, the presence of allelic variant D leads 
to an increased content of angiotensin II, a 
decrease in the level of bradykinin and may 
be a risk factor for the development of cardio-
vascular disease [16].
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To date, a number of data on the association 
of the ACE gene polymorphism with myocar-
dial infarction, sudden death, hypertension, left 
ventricular hypertrophy (LVH), hypertrophic 
cardiomyopathy, endothelial dysfunction, kid-
ney disease and microvascular complications 
of diabetes mellitus have been accumulated 
[16, 17]. In particular, it was found that the 
presence of allele D in the genotype of patients 
was associated with higher levels of BP (both 
systolic and diastolic), predisposition to the 
crisis course of hypertension and a signifi-
cantly higher severity of left ventricle myocar-
dial hypertrophy. The presence of genotype II 
in patients with hypertension, on the contrary, 
was associated with its asymptomatic course 
and a significantly later age of manifestation 
[18]. Additionally, it has been shown that the 
genotype DD is more common in the patients 
with CHD, diabetes mellitus and other risk 
factors (hyperlipidemia, smoking, family his-
tory of CVD) [16,17,19]. The DD variant of 
the genotype was associated with any myocar-
dial infarction, as well as a stroke and the 
development of AH [20].
The data of another study show that in the 
survey of a fairly large population (3145 peo-
ple) in the framework of Framingham study, 
it was found that the presence of the D-allele 
of the ACE gene in men is associated with a 
higher level of BP, especially the marked as-
sociation of D-allele was observed with the 
level of DBP. For women, such patterns were 
not found [21].
On the other hand, there is also evidence of 
the absence of association of the ACE poly-
morphism with hypertension. Later, the same 
author established that the connection is absent 
in the groups with a milder degree of hyperten-
sion, and in the persons with a malignant form 
of the DD genotype it occurs 3 times more 
often. The results of the initial studies were 
subsequently called into question in more ex-
tensive studies and through using randomized 
and well-organized groups. As a rule, many 
researchers do not take into account the popu-
lation and ethnic features of clinical material. 
In multifactorial diseases, the genetic system 
of polygenes is represented by a huge poly-
morphism of alleles of genes, the effects of 
which may be separately not so significant or 
manifested in certain circumstances. And be-
cause of ethnic diversity and high migration 
of people with different forms of hypertension 
it is impossible to bring the results to a com-
mon denominator. Therefore, the choice of 
methods for detecting the connection between 
polymorphisms with AH, the features of the 
studied groups, as well as the effect of hidden 
causes that determine the levels of BP and 
diagnosis of AH may be decisive in the find-
ings of the study.
The results showing the contingency of the 
allele D with the presence of abdominal obe-
sity were obtained. The relationship between 
abdominal obesity and the diagnosis of AH 
was of linear symmetric and mean strength. 
Thus, one can judge common genetic compo-
nent in the implementation of hypertensive 
disease and abdominal obesity [22].
Interesting data on the association of poly-
morphism of the ACE gene with endothelial 
dysfunction, as well as the processes of vas-
cular wall remodeling and atherogenesis are 
available. An increase in the activity of the 
local endothelial ACE is associated with a 
disturbed endothelium-dependent vasodilata-
tion on acetylcholine in the hereditary AH of 
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rats. This suggests that local hyperactivity of 
RAS can lead to the endothelial dysfunction.
On this basis, the attempts were made to 
link the endothelium dysfunction with the 
genotype of ACE. F.Perticone studied vaso-
dilation of the brachial artery in the patients 
with HD and healthy individuals in response 
to infusion of acetylcholine (endothelial-de-
pendent vasodilation) and sodium nitroprus-
side (endothelial-independent stimulus). At 
the same time, in the group of people with 
AH endothelial-dependent vasodilation was 
significantly less in the patients with DD 
genotype compared with the patients with 
II + ID genotype. In this case, endothelial-
independent vasodilation in these groups of 
patients did not differ significantly.Thus, the 
patients with DD genotype showed a greater 
degree of endothelial dysfunction, although 
they did not differ from the patients with II 
and ID genotypes in the level of BP, age, 
parameters of daily BP monitoring. In the 
group of healthy control such regularities 
were not revealed.
Among numerous candidate-genes, the type 
1 receptor gene to angiotensin II (AGTR1) also 
attracts attention because it mediates not only 
the vasoconstrictive action of angiotensin II, 
but also the expression of growth factors, the 
proliferation of smooth muscles, the release of 
tissue activator inhibitor Plasminogen and a 
number of other important effects [23].
Thus, the changes in expression or structure 
of the angiotensin II receptor of type 1 due to 
the polymorphism of its gene may lead to the 
changes in the regulation of vascular tone or 
proliferation of the elements of the vascular 
wall, so the gene of the angiotensin II receptor 
type 1 is considered as one of the candidate-
genes, associated with the pathology of the 
cardiovascular system.
The gene encoding the 1st type angiotensin 
II receptor (AGTR1) is located on chromo-
some 3 (3q24). The most actively studied is 
polymorphism А1166C (rs5186, a SNP known 
as +1166A/C or A1166C, is located in the 3’ 
untranslated region of the angiotensin II recep-
tor type 1 gene AGTR1), which leads to the 
replacement of adenine (A) with cytosine (C) 
in the 1166 position of the AGTR1 gene. B. 
Bonardeaux et al. have proved that the muta-
tion precisely in the 1166th position of the 
nucleotide sequence of the AGTR1 gene affects 
the functional activity of the receptor type 1 
of angiotensin II. Polymorphism of A1166C in 
AGTR1 was associated with CHD, as well as 
with myocardial infarction and the develop-
ment of AH [24].
There are interesting results of the study on 
the pulse wave velocity propagation and eval-
uation of the stiffness of large arteries in peo-
ple with AH and healthy people, depending on 
the genotype. The increased stiffness of the 
aorta with high probability was associated with 
the 1166CC genotype in people with AH.
Such a connection was not observed in 
people with normal pressure. The multiple 
regression analysis showed that the genotype 
of the angiotensin II receptor type 1 is the 
second after SBP level most important deter-
minant of aortic stiffness [25].
Equally important component of RAS is the 
protein — angiotensinogen (AGT).
The AGT gene is localized in the first chro-
mosome (locus 1 q42-43). In 1992, H. 
Jeunemaitre et al. for the first time confirmed 
the correlation between the AGT gene poly-
morphism and AH among Europeans and 
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Americans. 15 variants of the AGT gene were 
identified, but the association with the plasma 
levels of AGT and hypertension was detected 
only for both point mutations with the replace-
ment of threonine with methionine and me-
thionine with threonine in 174 and 235 gene 
codons — T174M (rs 4762, which is com-
monly referred to in the literature as “T174M” 
or “Thr174Met”; however, databases now in-
dicate that the amino acid that varies is #207 
(not 174, as the protein is currently numbered) 
and M235T (rs699, that is a SNP in the angio-
tensin AGT gene that encodes a functional 
change ??. In most published works, the name 
for this SNP is M235T, or perhaps Met235Thr, 
however its amino acid 268 (not 235) that var-
ies based on the numbering in todays data-
bases. rs699 is also occasionally known as 
C4072T. In any case, the rs699(C) allele en-
codes the threonine variant, which is associ-
ated with higher plasma angiotensin levels, 
and ultimately higher blood pressure leading 
to an increased risk for the hypertension as-
sociated disorders [17]), respectively, associ-
ated with the AGT activity levels of  blood 
plasma, with the content of AT II and, conse-
quently, with the risk of CVD. According to 
the literature, the presence of a 174M allele of 
the AGT gene is much more common in the 
patients with CHD, with myocardial infarction 
and LV hypertrophy [26]. In study on the 
M235T polymorphism, it was found that vari-
ant 235T is an independent factor in the risk 
of developing a heart attack, a risk factor for 
CHD. At the same time, it was found that the 
presence of one or two T-alleles led to a sub-
stantial increase in the level of AGT in plasma, 
resulting in a higher content of angiotensin II. 
It is a reason by which many authors explain 
the association of this polymorphism with AH. 
Sethi A. et al. conducted a meta-analysis, the 
purpose of which was to study the association 
of the AGT gene M235T polymorphism with 
the concentration of angiotensinogen in blood 
plasma, the level of systolic blood pressure 
(SBP) and diastolic blood pressure (DBP), AH 
and the risk of developing myocardial infarc-
tion and CHD. The study included three major 
ethnic groups: representatives of the Caucasian, 
Mongoloid and Negroid races. In representa-
tives of Caucasian races an increase in the 
concentration of AGT in plasma by 5 % in MT 
heterozygotes and by 11 % in homozygotes in 
the 235T allele was noted compared with the 
carriers of MM genotype. The M235T poly-
morphism of the AGT gene is associated with 
the risk of developing AH in Caucasians and 
indigenous people in Asia. However, in all 
three ethnic groups, this polymorphism was 
not associated with the risk of developing 
myocardial infarction and CHD [27].
Additionally, according to other studies, 
there is a correlation between the TT genotype 
of the M235T polymorphism of the AGT gene 
with a higher probability of development of AH, 
higher levels of BP and of concentration of ACE 
[28]. In another study of the M235T polymor-
phism it was demonstrated that the presence of 
one or two T-alleles is accompanied by a sig-
nificant increase in the level of AT II, which in 
turn, is able to trigger a cascade of inflamma-
tory reactions, leading to various disorders.
There is also an evidence of a correlation 
between the frequency of T/M allele of the 
M235T polymorphism of the AGT gene in 
hypertensive patients, which is 0.73/0.27. That 
is, the frequency of T-allele is almost twice 
higher in the patients suffering from AH [29].
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The M235T polymorphism of the AGT gene 
can promote the activation of immune inflam-
mation in the patients with AH. Thus, it was 
demonstrated that AH occurs and deepens in 
the individuals who are carriers of the gene 
of the T-allele of the M235T polymorphism of 
the AGT gene when the cytokine-interleu-
kine-1 (IL-1) and TNF-α concentrations are 
elevated. A high level, in particular IL-1, can 
promote inflammation, higher expression of 
AGT, and vasoconstriction of vessels in the 
patients with AH. That is, the M235T poly-
morphism of the AGT gene is a significant risk 
factor and a hereditary marker of the AH de-
velopment [30].
Characteristics of endothelial nitric 
oxide synthase gene polymorphisms 
of G894T, T-786C and 4th intron
At present, a significant amount of data on the 
association of polymorphisms of the eNOS 
gene with various diseases, including CVD, 
has been accumulated.
NO of endothelial origin is an important 
atheroprotector mediator, and the disorder of 
the regulation of its synthesis is associated 
with an increased risk of CVD. Hypertension 
develops in the NOS mouse line, and athero-
sclerosis develops in the line combining the 
absence of a functioning apolipoprotein E gene 
and the NOS gene (NOS3 is also known as 
eNOS) in the genome. Therefore, the pro-
cesses of regulation of the synthesis of NO and 
the gene encoding the NOS, are the first can-
didates in the study of endothelial dysfunction 
of blood vessels and a number of CVD [31]. 
Among the genes encoding NOS, the most 
likely candidate for the development of CVD 
is precisely the NOS3 gene.
The eNOS enzyme and NOS3 gene were 
described in 1992–1993. The gene encoding 
the eNOS is located on the chromosome 7q35-
36 and consists of 26 exons [32]. The eNOS 
gene promoter contains several domains, i.e. 
it can be controlled by a number of transcrip-
tion factors [33]. To date, the polymorphism 
of the eNOS gene in 11 locations has been 
described, 8 of which were studied as possible 
risk factors for CVD [34]. The most studied 
are the 4a/b polymorphism of 4th intron 
(27-bp-VNTR), the G894T (Glu298Asp) 
(rs1799983) polymorphism of the 7th exon and 
the T-786C (rs2070744) polymorphism of the 
eNOS gene promoter [35,36]. Fig.1.
The DNA region of the NOS3 gene, in 
which guanine (G) is replaced by thymine (T) 
in position 894, is called the genetic marker 
G894T. As a result of such a substitution, the 
properties of the protein are transformed, be-
cause in its amino acid sequence the glutamic 
amino acid at position 298 is replaced by as-
paraginic acid (Glu298Asp). The possible 
genotypes are G/G; T/T; G/T. A number of 
studies have shown that the people with geno-
type T/T have a higher risk of coronary heart 
disease (CHD), myocardial infarction and isch-
emic stroke. This is especially true in modern 
life, when the cardiovascular system of a per-
son is constantly subjected to various stresses. 
On the background of the genetic predisposi-
tion to CVD (the presence of allele T on SNP 
G894T of the NOS3 gene in the genotype) a 
probability of the pathology development in-
creases. The T-allele carriers (T/T and G/T 
genotypes) are more common in pregnant 
women who suffer from hypertension and 
placental abruption, compared to the group of 
women without these complications of preg-
340
T. V. Ashcheulova, N. N. Gerasimchuk, G. V. Demydenko et al.
nancy. Thus, the presence of T-allele is a po-
tential independent factor that increases the 
risk of developing hypertension in pregnan-
cy [37].
The literature presents contradictory infor-
mation on the relationship between the alleles 
of the polymorphism G894T and the content 
of NO in the blood. So, according to Dias R.G. 
et al [38], the TT genotype of G894T polymor-
phism causes an increase in the proteolytic 
activity in endothelial cells, leading to a de-
crease in the levels of functional eNOS and 
nitric oxide, and Sakar M. N. et al. [39] showed 
that the individuals with the TT genotype have 
statistically significantly lower NO level com-
pared to the subjects with GG or GT genotypes 
(p < 0.05). At the same time, Mackawy A.M. 
et al [40] found that the allele T of G894T 
polymorphism is associated with elevated lev-
els of nitrates in plasma: the content of plasma 
nitrates in the individuals with genotypes GG, 
GT and TT was 9.92 ± 1.65; 12.11 ± 1.04; 
14.55 ± 2.18 mmol/ml, respectively. In this 
regard, additional studies with a large number 
of subjects are needed to clarify this issue.
It is proved that the modification of the 
eNOS gene polymorphism is associated with 
the oxidative stress [41]. The role of gene poly-
morphism, in particular NOS3 (Glu298Asp), 
and end-product of glycosylation in the dif-
ferential response of cells to hyperglycemia has 
been studied.  It is shown that the presence of 
this genotype contributes to the development 
of endothelial-dependent vascular complica-
tions [42]. Several authors found that the 
G894T polymorphism of the NOS3 gene is a 
risk factor for coronary atherosclerosis and HD. 
At the same time, there may be a connection 
between the allele G of Glu298Asp polymor-
phism and the age of individuals with AH [43]. 
It has been shown that the polymorphism of 
eNOS — Glu298Asp (rs1799983) is associated 
with the BP levels in adolescents [44]. Besides, 
numerous studies have found that the endothe-
lium dependent vasodilatation in the presence 
of the 298Asp (894T) allele is damaged, and 
this type of polymorphism is connected with 
CHD and hypertension. 
Thus, it has been established that G894T 
polymorphism is associated with an increased 
carotid intimal medial thickness in the right 
carotid artery [45]. The association of the TT 
genotype with angina pectoris (odds ratio 
(OR) = 10.2; 95 % confidence interval 
Fig. 1. Polymorphism of the endothelial NO gene of synthase (eNOS) 
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(CI) = 1.51–68.8; P = 0.025) was found; in 
turn, the highest frequency of genotype GT 
occurrence was revealed in the individuals, 
who had relatives with coronary artery dis-
ease [46].
An analysis of literary sources on the data-
bases of Medline, Embase and Wangfang by 
January 1, 2013 with the participation of 8547 
patients and 9117 persons in the control group, 
showed that the genotype TT of G894T poly-
morphism is highly associated with the risk of 
developing ischemic stroke compared with the 
genotype of the allele G (OR = 1.25, 95 % 
CI = 1.09 -1.42, P < 0.001), which is more 
relevant for the Asian race than for the 
Caucasian race [47]. A meta-regression analy-
sis devoted to the establishment of associations 
between HD and the polymorphic variant of 
G894T in the Han ethnic group (China) showed 
a positive relationship (OR = 1.32, P < 0.001), 
whereas geographic differences were identified 
in the relationship between G894T and predis-
position to this disease. Thus, among the resi-
dents of the southern regions of China the 
indicated polymorphism may be related to HD 
(OR = 1.59, P < 0.001), whereas in the north-
ern regions such association is not observed 
(OR = 1.16, P = 0.12) [48].
 In the individuals suffering from excessive 
body weight, the T allele of the G894T poly-
morphism of the NOS3 gene increases the risk 
of hypertension development [49]. There was 
established an increased risk of developing 
obesity in the presence of the TT G894T gen-
otype (OR = 2.62, P = 0.04),  whereas the 
gender analysis shows that in men with over-
weight this genotype is found much more often 
compared to the control group (9.9 % versus 
2.9 %, P = 0.01) [50].
Moreover, the authors investigated the re-
lationship between the main effector of the 
renin-angiotensin system AT II and allelic 
polymorphism G894T of the eNOS gene. It has 
been established that this type of polymor-
phism determines the systemic and renal he-
modynamic response to AT II. This effect is 
more pronounced in men than in women [51]. 
In this regard it is of scientific and practical 
interest to study the combined effect of the 
common polymorphism on the insertion/dele-
tion of the ACE gene and the allele 894T of 
the eNOS gene on the development of endo-
thelial dysfunction, hypertension, atheroscle-
rosis, and nephropathyis.
One of the most studied variants of the 
eNOS polymorphism is tandem repeats in the 
intron 4 (4a/b) (rs869109213. In intron 4 of 
this gene minisatellite eNOS 4a/4b is located, 
which has two alleles, consisting of 4 or 5 
tandem repeats in size of 27 pairs of nucleo-
tides. The normal version contains 5 repeats 
(denoted as 4b), the mutant variant contains 4 
repeats (denoted as 4a). 
The variants of polymorphism: 4b/4b — 
normal variant of polymorphism in a homozy-
gous form; 4b/4a — heterozygous form of 
polymorphism; 4a/4a — mutant variant of 
polymorphism associated with the increased 
risk of disease in a homozygous form.
The effect of variant 4a is associated with 
a disorder of the expression of the  NOS3 gene, 
which leads to a decrease in the NO produc-
tion. For this variant, the associations with 
atherosclerosis, CHD and myocardial infarc-
tion are described. In the patients with type 2 
diabetes, the presence of option 4a is a risk 
factor for hypertension. In 2004 S.Fatini et al. 
showed a connection between the genotype 4a 
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/ 4a and the onset of acute coronary syndrome, 
in particular with an acute myocardial infarc-
tion [52]. Additionally, in 2012, Chinese sci-
entists in the meta-analysis of American pa-
tients have linked the 4a/4a genotype with an 
increased risk of ischemic stroke [53].
Most authors have shown that the presence 
of allele C in position 786 of the promoter of 
the eNOS gene results in a decrease in its activ-
ity by 52 ± 11 %, and the resulting lack of 
eNOS is responsible for a decrease in the syn-
thesis and release of nitric oxide and endothe-
lial dysfunction [54]. In the people with path-
ological genotype of the promoter of the eNOS 
gene (CC and TC) it was observed an increase 
in the tone of coronary arteries, increased pro-
pensity to coronar spasm and perverted coro-
nary artery reaction to the introduction of ace-
tylcholine, which can serve as the basis for the 
development of coronary heart disease (CHD) 
and HD [55]. It was shown that the polymor-
phism of -786T > C promoter is associated 
with an increased risk of restenosis after the 
stenting of coronary arteries [56].
When screening the population to determine 
the prevalence of -786T > C (rs2070744) poly-
morphism in the 5’- untranslated region of the 
gene eNOS and its association with pathology, 
it was found that homozygotes -786C are more 
common among the patients with atheroscle-
rosis of the coronary arteries than in the control 
group (24.6 % versus 14.5 %). The risk of the 
pathology development was higher in the ho-
mozygote CC compared with the homozygotes 
TT [57].
The association of polymorphism -786T > C 
with the type of vascular reaction to the load 
was also found among juvenile Caucasian race. 
In boys (168 persons) with a hypertensive 
response to the load the genotype of CC was 
found 3.5 times more often. Such CC homo-
zygotes are characterized by a higher periph-
eral vascular tone and an imbalance of produc-
tion of major vasoactive endothelial factors, 
which is manifested in elevated endothelin-1. 
It is typical that hypertonic vascular responses 
to load are noted in the individuals with a 
failure of regulatory mechanisms of supporting 
the vascular tone, as well as in those with HD 
and pre-hypertension [58].
Noteworthy, this study focused on the per-
sons with for the moment compensated state 
of vascular factors, the imbalance of which is 
revealed only with certain tests. Distinguishing 
such a group with a hidden pathology of CVD 
and defining the NOS3 gene polymorphism in 
it would help to study the implementation of 
a particular allele in the phenotype.
Meta-analysis of Casas et al. showed that 
the mutation –786T > C in the promoter region 
of the eNOS gene affects the level of gene 
expression. A low level of the mRNA of the 
eNOS gene as well as a low serum nitrate/ni-
trite level are noted in the individuals with the 
variant –786C [59]. 
In Canada, 705 middle-aged men without 
CHD in their history were involved in the 
study of M.E. Hyndman et al. [60]. The ratio 
of different variants of the genotype (TT, TC, 
and CC) of the promoter of the eNOS gene was 
close to that of the Caucasians and was dis-
tributed respectively 38.9; 46.1 and 15.0 %. 
The persons with CC genotype had markedly 
higher levels of SBP and were more often 
diagnosed with AH which allowed the authors 
to conclude that the CC genotype of eNOS 
gene promoter is a risk factor in the develop-
ment of AH.
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In 2013, the data on the association of eNOS 
gene polymorphisms 4b/4a, T-786C and G894T 
with metabolic syndrome (MS) have been pub-
lished. The study included 339 patients with 
MS and 783 patients without MS who were 
treated at the Central Taiwanese Hospital. The 
variant ТС+СС on T-786C SNP of the eNOS 
gene was significantly associated with a de-
crease in the risk of MS (OR = 0.63). Intron 
4b/ 4a genotype of intron 4 27bp repeat poly-
morphism of the eNOS gene is also associated 
with a decrease in the risk of MS (OR = 0.68). 
Additionally, the authors have shown that the 
presence of the G894T genotype in obese sub-
jects plays a significant role in comparison with 
the control group (OR = 1.65) [61]. J. Bressler, 
J.S. Pankow, J. Coresh, E. Boerwinkle analyzed 
the polymorphism of the eNOS gene (G894T) 
and obesity as a risk determinant for AH, DM 
type 2 in 14,374 participants from the United 
States in the framework of a joint study in 
2013. Among the participants there were 728 
patients with DM type 2 (African-Americans) 
and 980 — of Caucasian race. The study shows 
that the relationship between the indicated pa-
rameters is noted only in the individuals of the 
Caucasian race [62]. 
Additionally it was noted that for the Italian 
population two types of the eNOS gene poly-
morphisms are associated with significant an-
giographical changes. The scientists suggest 
that the combination of two types of polymor-
phisms T786C and Glu298Asp in one genome 
is associated with a high risk of developing 
CHD and HD compared to one type [63]. Thus, 
this study demonstrates the importance of iden-
tifying not a single polymorphism, but their 
combination to distinguish the risk groups in 
CHD and HD.  
A four-SNP haplotype, comprising an un-
common variant rs11699009 in the BPIFB4 
gene, has been associated with notable longe-
vity. In the study of Vecchione et al. [64], 416 
individuals were genotyped to determine their 
haplotypes. The authors demonstrated that the 
overexpression of the BPIFB4 uncommon 
variant in mice impaired eNOS signaling and 
increased BP, opening the way for the develop-
ment of new therapeutic strategies.Тhe present 
study demonstrates that the expression of a 
rare variant of BPIFB4 — a protein we have 
previously associated with improved aging 
when present in its longevity-associated iso-
form — leads to the maintenance of high blood 
pressure in the face of treatment  of hyperten-
sion. 
Noteworthy, a number of studies did not 
reveal the relationship between the polymor-
phism of the NOS3 gene and the development 
of CVD, which may be due to the small sam-
ple size in these studies or ethnicity etc.
Data from Next-Generation 
Sequencing technology 
at hypertension with obesity
The cause of a complex trait, like essential 
hypertension, remains elusive if examined in 
the light of the GWAS results. Data from NGS 
technology offer the possibility to capture a 
greater range of the single nucleotide variabil-
ity compared to GWAS.
Genetic variants associated with hyperten-
sion, obesity and diabetes based on PolyPhen2 
and SIFT algorithmic predictors of mutation 
pathogenicity were analyzed on the complete 
exome of 60 people of Kazakh nationality us-
ing the technology of Next-Generation 
Sequencing (NGS) HiSeq2000. 
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Seven genetic variants were detected in 
GHRL (rs4684677), MTHFR (rs1801133), 
OPRM1 (rs1799971), ERBB2 (rs1058808), 
BDNF (rs6265), PNPLA3 (rs738409), MTRR 
(rs1801394) genes [65]. 
The group of Kim et al. [66] interrogated 
135 Exome Chip SNVs for associations with 
ten cardiometabolic traits in 14,028 Korean 
individuals. Three associations were observed 
with one or more of four cardio-metabolic 
traits (fasting plasma glucose (FPG), waist-hip 
ratio (WHR), Systolic Blood Pressure (SBP), 
Diastolic Blood Pressure (DBP),) within the 
genes BRAP, ACAD10 and ALDH2 in the 
12q24.12 region. The pleiotropic effect of 
region 12q24.12 was identified for three SNPs 
(rs3782886 on BRAP, rs11066015 on ACAD10 
and rs671 on ALDH2) on lipids and other 
cardio-metabolic traits. The locus was also 
associated with High-Density Lipoprotein 
(HDL), Low-Density Lipoprotein (LDL), tri-
glycerides (p < 1.06 × 10−2 ; effect sizes be-
tween −7.60 ± 1.72 and 2.55 ± 0.53) [66].
Conclusions
The study on the polymorphism of the renin-
angiotensin system genes and the endothelial 
synthase nitrogen oxide gene is of great prac-
tical importance, since it not only provides an 
opportunity to predict the complications of 
hypertension disease but  is also the basis for 
obtaining the expression of positive gene com-
binations.Thus, the analysis of literature data 
suggests that identified genotype-phenotype 
associations and corresponding functional 
changes in the endothelium can give informa-
tion about the possibilities of priority and op-
timal therapeutic effects in each case, will 
enable  optimization of the diagnosis of disor-
ders in patients with combined pathology — 
hypertension and obesity, at the early stages. 
The advent of Next-Generation Sequencing 
provided the opportunity to detect, in a high-
throughput way, the entire spectrum of ge-
nomic variation ranging from rare to common 
variants and from Single Nucleotide 
Polymorphism to insertions, deletions.
However, the analysis of works on this sub-
ject showed that in studying the association of 
the polymorphism of the renin-angiotensin 
system genes and the endothelial synthase ni-
trogen oxide gene with the development of 
cardiovascular diseases, namely, hypertension 
with obesity, one must take into account both 
the ethnic belonging of the subjects and a com-
position of polymorphous variants, and their 
combinations in  the  sample of a larger  size.
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Поліморфізм генів ренін-ангіотензинової 
системи та гена ендотеліальної no-синтази у 
хворих на артеріальну гіпертензію з ожирінням
Т. В. Ащеулова, Н. М. Герасимчук, 
Г. В. Демиденко, М. В. Кулікова
У статті представлений клінічно встановлений 
взаємозв’язок підвищеного артеріального тиску зі збіль-
шенням маси тіла. Показано, що ендотеліальна дис-
функція і дисбаланс нейро-гуморальних систем, а саме 
патологічне підвищення активності ренін-ангіотензи-
нової системи, виступають провідними механізмами 
патогенезу гіпертонічної хвороби в поєднанні з ожи-
рінням. Даний огляд літератури присвячений інтер-
претації наукових досліджень в області поліморфізму 
генів ренін ангіотензинової сиcтеми і гена ендотеліаль-
ної синтази оксиду азоту. Складність полягає в пра-
вильній оцінці асоціацій алелей, які мають клінічне 
значення. Особливо важливо завжди точно визначати 
асоціації поліморфізму генів при гіпертонічній хворо-
бі з ожирінням. Інформація про подібні асоціації і 
зв’язки надає можливість для пошуку нових тактик і 
мішеней впливу, що розвиває персоніфіковані підходи 
до терапії пацієнтів з даною комплексною патологією.
К л юч ов і  с л ов а: ендотеліальна синтаза оксиду 
азоту, ренін-ангітензінова система, поліморфізм генів, 
гіпертонічна хвороба, ожиріння.
Полиморфизм генов ренин-ангиотензиновой 
системы и гена эндотелиальной no-синтазы 
у больных артериальной гипертензией 
с ожирением
Т. В. Ащеулова, Н. Н. Герасимчук, 
А. В. Демиденко, М. В. Куликова
В статье представлены данные о взаимосвязи повы-
шения уровня артериального давления и увеличения 
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массы тела. Показано, что эндотелиальная дисфункция 
и дисбаланс нейрогуморальных систем, а именно па-
тологическое повышение активности ренин-ангиотен-
зиновой системы выступают ведущими механизмами 
патогенеза гипертонической болезни в сочетании с 
ожирением. Данный обзор литературы посвящён ин-
терпретации научных изысканий в области полимор-
физма генов ренин ангиотензиновой сиcтемы и гена 
эндотелиальной синтазы оксида азота. Трудность за-
ключается в правильной оценке ассоциаций аллелей, 
которые имеют клиническое значение. Особенно важ-
но точное определение ассоциаций полиморфизма 
генов при гипертонической болезни с ожирением. 
Информация о подобных ассоциациях и связях предо-
ставляет возможности для поиска новых тактик и 
мишеней для воздействия, что развивает персонифи-
цированные подходы к терапии пациентов с данной 
комплексной патологией.
К л юч е в ы е  с л ов а: эндотелиальная синтаза окси-
да азота, ренин-ангитензиновая система, полиморфизм 
гена, гипертоническая болезнь, ожирение.
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